BUY

TARGET PRICE: 6,6€ (vs 7,3€)

+141%

UPDATE

INCREASED VISIBILITY, CLINICAL POTENTIAL CONFIRMED

We have updated our model to include the €20m private placement that has extended the financial visibility up through Q1 23. Since our last flash, the company has announced encouraging new clinical data for iademenstat and vafidemstat, its two drug candidates in the treatment respectively of AML and psychiatric disorders. This data, which is consistent with already reported results, confirms the potential of the pipeline but has not led to any change in our valuation for the moment. We have adjusted our target price to €6.6 (vs. €7.3) and are maintaining our BUY opinion.

Thibaut Voglimacci -Stephanopoli +33 1 44 88 77 95 tvoglimacci@invest-securities.com

Capital increase totaling €20m, financial visibility up through Q1 23

The H1 20 results were marked by slightly higher than expected OPEX despite a difficult health context that has affected the pursuit of the clinical trials. In greater detail, OPEX rose +18% to -\$8.9m (vs. -\$8.1m expected), boosted by the increase in R&D spending (+26%) in connection of the development of the pipeline. The net loss equaled -\$1.5m (vs. -\$2.2m expected). As of end June 2020, cash totaled \$54.9m, reflecting the completion of a \$22.4m private placement last June 25. This placement involved the creation of 7.273 million new shares at a price of €2.75 per share, corresponding to a -10.7% discount to the previous share price. This fundraising round has extended the financial visibility up through Q1 23 and represents further confirmation of the market's interest in the company's epigenetic approach. Additionally, this supplemental financing will enable the company to easily deal with the current environment and serenely enter into potential negotiations for licenses covering its drug candidates once the phase II trials are completed. We would note the company is not ruling out a dual listing on the NASDAQ in order to raise additional funds that would give it the option of in-house development and to give it visibility in the United States.

Additional clinical data that is consistent and encouraging

On June 12, the company announced additional data from its phase II ALICE trial evaluating iadademstat + azacitidine in the treatment of acute myeloid leukemia (AML) in elderly patients. This data from 13 patients was presented in connection with the EHA-2020 meeting. The efficacy data was consistent overall with that presented in connection with eight patients last December 9. The response rate for the 13 patients was 77% compared to 75% for the previous eight patients. In greater detail, 60% of these patients showed complete remission (CR) versus 83% previously and 40% showed partial remission (PR) versus 17% previously. The longest remission was 488 days. The mean time to response was 37 days versus 32 days for the previous eight patients. As a reminder, the historical response rate in this population with azacitidine alone is 27%. In the same target population, Venclexta (ABBVIE) + azacitidine reached a response rate of 67% in a clinical trial involving 145 patients. By way of illustration, the Evaluate Pharma consensus anticipates 2026 sales of €2.6bn for this combination. Even if coming from a limited sample, these results demonstrate the potential of iademenstat. The ALICE study calls for a recruitment of 36 patients in total. 1/5

in € / share	2020e	2021e	2021e
Adjusted EPS	-0,09	-0,21	0,58
chg.	n.s.	n.s.	n.s.
estimates chg.	n.s.	n.s.	n.s.
au 31/12	2020e	2021e	2021e
PE	n.s.	n.s.	n.s.
EV/Sales	n.s.	n.s.	n.s.
EV/EBITDA	n.s.	n.s.	n.s.
EV/EBITA	n.s.	n.s.	n.s.
FCF yield*	n.s.	n.s.	n.s.
Div. yield (%)	n.s.	n.s.	n.s.

EV/EBITA	n.s.	n.s.	n.s.		1m	3m	Ytd
FCF yield*	n.s.	n.s.	n.s.	Absolute perf.	+2,4%	-23,4%	-1,4%
Div. yield (%)	n.s.	n.s.	n.s.	Relative perf.	+4,4%	-29,3%	+16,3%
* After tax op. FCF b	oefore WCR			Source : I	actset, Inve	st Securities	estimates

ISIN

Ticker DJ Sector

Share price (€) Number of Shares (m)

Market cap. (€m)

Free float (€m)


53,1

145

ES0167733015 ORY-FS

Health Technology

More recently, Oryzon presented at the beginning of July in connection with the EPA 2020 meeting final data from its REIMAGINE trial evaluating vafidemstat in three major psychiatric disorders: BPD (Borderline Personality Disorder), ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder). The data presented came from 30 patients (12 BPD, 11 ADHD and seven ASD). In comparison, the initial results already presented at different meetings in 2019 involved six patients with BPD (flash dated May 6, 2019), six patients with ADHD (flash dated May 6, 2019) and six patients with ASD (flash dated September 18, 2019). The final data was consistent with the encouraging data previously presented in terms of the different scales (CGI-S, CG-I, NPI-A/A) evaluating the control of agitation and aggression in patients. At the same time, a general improvement was observed using other regularly used scales (BPDCL, C-SSRS, ADHD-RS). In contrast, the most significant and encouraging improvement involved the cohort of patients suffering from BPD, with a remarkable improvement on the BPDCL scale (see chart below), suggesting that vafidemstat has a psychiatric effect beyond agitation and aggression. In greater detail, a score above 100 on the BPDCL scale indicates a bipolar disorder while a score of 67 corresponds to a clinical recovery cut-off.



Source : Oryzon Genomics

Bolstered by these results in BPD, the company plans to launch a phase IIb clinical trial in this indication over the near future. This study, to be called PORTICO, will be a double-blind, placebo-controlled, multicenter study and should include a sufficient number of patients to attain statistical significance. The initial design mentioned in different presentations involved a total of 100 patients over 16 weeks, corresponding to two times the length of treatment in the REIMAGINE study. The start of recruitment for this study has been delayed for a few months due to the Covid-19 pandemic.

Target price adjusted to €6.6 (vs. €7.7 previously), BUY opinion maintained

While we are not modifying our P&L estimates and our rNPV valuation, we have integrated into our model the €20m private placement that has led to the creation of 7.273 million new shares, resulting in -14% dilution. We have adjusted our target price to €6.6 (vs. €7.3 previously). With upside potential of +133% and an increasingly mature broad-based pipeline in high potential indications, we are maintaining our BUY opinion.



INVESTMENT CASE

ORYZON is a Spanish biotech specializing in the treatment of neurodegenerative diseases and cancer. In all its development programs, the company identifies biomarkers through its genetic and proteomic platforms in order to develop small molecule drugs. Looking ahead of multiple clinical updates, we believe that Oryzon's lead programs could significantly advance in 2020/2021.

FINANCIAL DATA

Carlos Manuel Buesa Arjo Tamara 7,196 Maes 7,196 Others 9,696

Share information	2017	2018	2019	2020e	2021e	2022e	2023e	2024e
Published EPS (€)	-0,15	-0,03	-0,09	-0,09	-0,21	0,58	0,49	0,81
Adjusted EPS (€)	-0,15	-0,03	-0,09	-0,09	-0,21	0,58	0,49	0,81
Diff. I.S. vs Consensus	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.
Dividend	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00
Valuation ratios	2017	2018	2019	2020e	2021e	2022e	2023e	2024e
P/E	n.s.	n.s.	n.s.	n.s.	n.s.	4,7x	5,6x	3,4x
EV/Sales	n.s.	n.s.	n.s.	n.s.	n.s.	2,42x	4,10x	0,85x
VE/EBITDA	n.s.	n.s.	n.s.	n.s.	n.s.	3,4x	4,8x	1,9x
VE/EBITA	n.s.	n.s.	n.s.	n.s.	n.s.	3,4x	4,8x	1,9x
Op. FCF bef. WCR yield	n.s.	n.s.	n.s.	n.s.	n.s.	13,5%	11,5%	32,6%
Op. FCF yield	n.s.	n.s.	n.s.	n.s.	n.s.	13,5%	11,5%	32,6%
Div. yield (%)	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.
NB: valuation based on annual				11.5.	11.5.	11.5.	11.5.	11.5.
Entraprise Value (Cm)	2017	2040	2040	2020-	20246	2022e	20220	2024e
Entreprise Value (€m)		2018	2019	2020e	2021e		2023e	
Share price in €	<i>4,6</i>	2,7	3,2	<i>2,7</i>	<i>2,7</i>	<i>2,7</i>	2,7	<i>2,7</i>
Market cap.	156	94	148	133	133	133	133	133
Net Debt	-17	-23	-27	-13	5	-12	-24	-51
Minorities	0	0	0	0	0	0	0	0
Provisions/ near-debt	0	0	0	0	0	0	0	0
+/- Adjustments Entreprise Value (EV)	0 139	<u> </u>	0 122	0 119	0 137	0 121	109	0 82
Littleprise value (LV)	103	- ''	122	113	107	121	103	02
Income statement (€m)	2017	2018	2019	2020e	2021e	2022e	2023e	2024e
Sales	0,0	0,0	0,0	0,0	0,0	50,0	26,5	96,3
chg.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.
EBITDA	-4	-3	-4	-4	-9	35	23	42
EBITA	-4	-3	-4	-4	-9	35	23	42
chg.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	<i>-35,59</i> 6	+84,6%
EBIT	-4,7	-3,3	-3,8	-4,0	-9,0	34,9	22,3	41,5
Financial result	-1	-1	-1	-1	-1	-1	-1	-1
Corp. tax	0	3	1	1	1	-9	0	-5
Minorities+affiliates	0	0	0	0	0	0	0	0
Net attributable profit	-5,2	-1,2	-3,8	-3,9	-9,0	25,4	21,5	35,6
Adjusted net att. profit	-5,2	-1,2	-3,8	-3,9	-9,0	25,4	21,5	35,6
<u>chg.</u>	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	<i>-15,49</i> 6	+65,8%
Cash flow statement (€m)	2017	2018	2019	2020e	2021e	2022e	2023e	2024e
EBITDA	-3,9	-3,1	-3,7	-3,7	-8,7	35,3	22,7	42,0
Theoretical Tax / EBITA	0,1	2,5	0,9	0,9	0,9	-8,7	0,0	-5,1
Capex					-10,3	-10,3	-10,3	-10,3
Сирск	0,6	-7,0	-9,6	-10,3	10,5			~~ -
Operating FCF bef. WCR	0,6 -3,2		-9,6 -12,4	-10,3 -13,1	-18,1	16,3	12,5	26,7
		-7,0						2 6,7 0,0
Operating FCF bef. WCR	-3,2	-7,0 -7,6	-12,4	-13,1	-18,1	16,3	12,5	
Operating FCF bef. WCR Change in WCR	-3,2 -0,2	-7,0 -7,6 0,3	-12,4 0,3	-13,1 0,0	-18,1 0,0	16,3 0,0	12,5 0,0	0,0
Operating FCF bef. WCR Change in WCR Operating FCF	-3,2 -0,2 -3,4	-7,0 - 7,6 0,3 - 7,3	-12,4 0,3 -12,1	-13,1 0,0 -13,1	-18,1 0,0 -18,1	16,3 0,0 16,3	12,5 0,0 12,5	0,0 26,7
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals	-3,2 -0,2 -3,4 5,1	-7,0 - 7,6 0,3 - 7,3 0,1	-12,4 0,3 -12,1 0,5	-13,1 0,0 -13,1 0,0	-18,1 0,0 -18,1 0,0	16,3 0,0 16,3 0,0	12,5 0,0 12,5 0,0	0,0 26,7 0,0
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid	-3,2 -0,2 -3,4 5,1 16,9 0,0	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0	-12,4 0,3 -12,1 0,5 18,4 0,0	-13,1 0,0 -13,1 0,0 20,0 0,0	-18,1 0,0 -18,1 0,0 0,0	16,3 0,0 16,3 0,0 0,0	12,5 0,0 12,5 0,0 0,0	0,0 26,7 0,0 0,0
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease	-3,2 -0,2 -3,4 5,1 16,9	-7,0 -7,6 0,3 -7,3 0,1 11,9	-12,4 0,3 -12,1 0,5 18,4	-13,1 0,0 -13,1 0,0 20,0	-18,1 0,0 -18,1 0,0 0,0 0,0	16,3 0,0 16,3 0,0 0,0 0,0	12,5 0,0 12,5 0,0 0,0 0,0	0,0 26,7 0,0 0,0 0,0
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow	-3,2 -0,2 -3,4 5,1 16,9 0,0 0,0 18,5	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7	-13,1 0,0 -13,1 0,0 20,0 0,0 0,0 6,9	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1	16,3 0,0 16,3 0,0 0,0 0,0 0,0 0,0	12,5 0,0 12,5 0,0 0,0 0,0 0,0 12,5	0,0 26,7 0,0 0,0 0,0 0,0 0,0 26,7
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m)	-3,2 -0,2 -3,4 5,1 16,9 0,0 0,0 18,5	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7	-13,1 0,0 -13,1 0,0 20,0 0,0 0,0 6,9	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3	12,5 0,0 12,5 0,0 0,0 0,0 0,0 12,5	0,0 26,7 0,0 0,0 0,0 0,0 26,7
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets	-3,2 -0,2 -3,4 5,1 16,9 0,0 0,0 18,5	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7	-13,1 0,0 -13,1 0,0 20,0 0,0 0,0 6,9 2020e 52	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1 2021e 62	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 72	12,5 0,0 12,5 0,0 0,0 0,0 0,0 12,5 2023e 82	0,0 26,7 0,0 0,0 0,0 0,0 26,7 2024e 91
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW	-3,2 -0,2 -3,4 5,1 16,9 0,0 0,0 18,5 2017 25 22	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40	-13,1 0,0 -13,1 0,0 20,0 0,0 0,0 6,9 2020e 52 50	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1 2021e 62 60	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 72	12,5 0,0 12,5 0,0 0,0 0,0 0,0 12,5 2023e 82 79	0,0 26,7 0,0 0,0 0,0 0,0 26,7 2024e 91 89
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR	-3,2 -0,2 -3,4 5,1 16,9 0,0 0,0 18,5 2017 25 22 -8	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29 -9	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40 -8	-13,1 0,0 -13,1 0,0 20,0 0,0 0,0 6,9 2020e 52 50 -8	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1 2021e 62 60 -8	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 72 70 -8	12,5 0,0 12,5 0,0 0,0 0,0 0,0 12,5 2023e 82 79 -8	0,0 26,7 0,0 0,0 0,0 26,7 2024e 91 89 -8
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital	-3,2 -0,2 -3,4 5,1 16,9 0,0 0,0 18,5 2017 25 22 -8 34	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29 -9 45	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40 -8 61	-13,1 0,0 -13,1 0,0 20,0 0,0 6,9 2020e 52 50 -8 77	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1 2021e 62 60 -8 68	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 72 70 -8 94	12,5 0,0 12,5 0,0 0,0 0,0 12,5 2023e 82 79 -8 115	0,0 26,7 0,0 0,0 0,0 0,0 26,7 2024e 91 89 -8 151
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders	-3,2 -0,2 -3,4 5,1 16,9 0,0 18,5 2017 25 22 -8 34 0	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29 -9 45 0	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40 -8 61 0	-13,1 0,0 -13,1 0,0 20,0 0,0 0,0 6,9 2020e 52 50 -8 77 0	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1 2021e 62 60 -8 68 0	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 72 70 -8 94 0	12,5 0,0 12,5 0,0 0,0 0,0 0,0 12,5 2023e 82 79 -8 115 0	0,0 26,7 0,0 0,0 0,0 0,0 26,7 2024e 91 89 -8 151 0
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital	-3,2 -0,2 -3,4 5,1 16,9 0,0 0,0 18,5 2017 25 22 -8 34	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29 -9 45	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40 -8 61	-13,1 0,0 -13,1 0,0 20,0 0,0 6,9 2020e 52 50 -8 77	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1 2021e 62 60 -8 68	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 72 70 -8 94	12,5 0,0 12,5 0,0 0,0 0,0 12,5 2023e 82 79 -8 115	0,0 26,7 0,0 0,0 0,0 0,0 26,7 2024e 91 89 -8 151
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt	-3,2 -0,2 -3,4 5,1 16,9 0,0 18,5 2017 25 22 -8 34 0 0 -17,2	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29 -9 45 0 0 -22,6	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40 -8 61 0 0 -26,7	-13,1 0,0 -13,1 0,0 20,0 0,0 0,0 6,9 2020e 52 50 -8 77 0 0 -13,4	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1 2021e 62 60 -8 68 0 0 4,7	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 72 70 -8 94 0 0 -11,6	12,5 0,0 12,5 0,0 0,0 0,0 12,5 2023e 82 79 -8 115 0 0 -24,1	0,0 26,7 0,0 0,0 0,0 0,0 26,7 2024e 91 89 -8 151 0 0 -50,7
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios	-3,2 -0,2 -3,4 5,1 16,9 0,0 18,5 2017 25 22 -8 34 0 0 -17,2	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29 -9 45 0 0 -22,6	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40 -8 61 0 0 -26,7	-13,1 0,0 -13,1 0,0 20,0 0,0 0,0 6,9 2020e 52 50 -8 77 0 0 -13,4	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1 2021e 62 60 -8 68 0 0 4,7	16,3 0,0 16,3 0,0 0,0 0,0 16,3 2022e 72 70 -8 94 0 0 -11,6	12,5 0,0 12,5 0,0 0,0 0,0 12,5 2023e 82 79 -8 115 0 -24,1	0,0 26,7 0,0 0,0 0,0 0,0 26,7 2024e 91 89 -8 151 0 0 -50,7
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios EBITDA margin	-3,2 -0,2 -3,4 5,1 16,9 0,0 0,0 18,5 2017 25 22 -8 34 0 0 -17,2 2017 n.s.	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29 -9 45 0 -22,6	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40 -8 61 0 0 -26,7	-13,1 0,0 -13,1 0,0 20,0 0,0 6,9 2020e 52 50 -8 77 0 0 -13,4	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1 2021e 62 60 -8 68 0 0 4,7	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 70 -8 94 0 0 -11,6	12,5 0,0 12,5 0,0 0,0 0,0 12,5 2023e 82 79 -8 115 0 -24,1 2023e 85,9%	0,0 26,7 0,0 0,0 0,0 26,7 2024e 91 89 -8 151 0 -50,7
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios EBITDA margin EBITA margin	-3,2 -0,2 -3,4 5,1 16,9 0,0 0,0 18,5 2017 25 22 -8 34 0 0 -17,2 2017 n.s. n.s.	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29 -9 45 0 0 -22,6 2018 n.s. n.s.	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40 -8 61 0 0 -26,7 2019 n.s. n.s.	-13,1 0,0 -13,1 0,0 20,0 0,0 6,9 2020e 52 50 -8 77 0 0 -13,4 2020e n.s.	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1 2021e 62 60 -8 68 0 0 4,7 2021e n.s.	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 72 70 -8 94 0 0 -11,6 2022e 70,6% 70,6%	12,5 0,0 12,5 0,0 0,0 0,0 12,5 2023e 82 79 -8 115 0 0 -24,1 2023e 85,9% 85,9%	0,0 26,7 0,0 0,0 0,0 0,0 26,7 2024e 91 89 -8 151 0 0 -50,7
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios EBITDA margin EBITA margin Adjusted Net Profit/Sales	-3,2 -0,2 -3,4 5,1 16,9 0,0 18,5 2017 25 22 -8 34 0 0 -17,2 2017 n.s. n.s.	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29 -9 45 0 0 -22,6 2018 n.s. n.s.	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40 -8 61 0 0 -26,7 2019 n.s. n.s.	-13,1 0,0 -13,1 0,0 20,0 0,0 0,0 6,9 2020e 52 50 -8 77 0 0 -13,4 2020e n.s. n.s.	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 0,0 -18,1 2021e 62 60 -8 68 0 0 4,7 2021e n.s. n.s.	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 72 70 -8 94 0 0 -11,6 2022e 70,6% 70,6% 50,7%	12,5 0,0 12,5 0,0 0,0 0,0 12,5 2023e 82 79 -8 115 0 0 -24,1 2023e 85,9% 85,9% 81,1%	0,0 26,7 0,0 0,0 0,0 0,0 26,7 2024e 91 89 -8 151 0 0 -50,7
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios EBITDA margin EBITA margin Adjusted Net Profit/Sales ROCE	-3,2 -0,2 -3,4 5,1 16,9 0,0 18,5 2017 25 22 -8 34 0 0 -17,2 2017 n.s. n.s.	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29 -9 45 0 0 -22,6 2018 n.s. n.s.	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40 -8 61 0 0 -26,7 2019 n.s. n.s.	-13,1 0,0 -13,1 0,0 20,0 0,0 0,0 6,9 2020e 52 50 -8 77 0 0 -13,4 2020e n.s. n.s.	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 0,0 -18,1 2021e 62 60 -8 68 0 0 4,7 2021e n.s. n.s.	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 72 70 -8 94 0 0 -11,6 2022e 70,6% 50,7% 55,1%	12,5 0,0 12,5 0,0 0,0 0,0 0,0 12,5 2023e 82 79 -8 115 0 0 -24,1 2023e 85,9% 81,1% 30,8%	0,0 26,7 0,0 0,0 0,0 0,0 26,7 2024e 91 89 -8 151 0 0 -50,7 2024e 43,6% 43,6% 37,0% 50,3%
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios EBITDA margin EBITA margin Adjusted Net Profit/Sales ROCE ROCE ROCE adjusted	-3,2 -0,2 -3,4 5,1 16,9 0,0 18,5 2017 25 22 -8 34 0 0 -17,2 2017 n.s. n.s. n.s.	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29 -9 45 0 0 -22,6 2018 n.s. n.s. n.s.	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40 -8 61 0 0 -26,7 2019 n.s. n.s. n.s.	-13,1 0,0 -13,1 0,0 20,0 0,0 0,0 6,9 2020e 52 50 -8 77 0 0 -13,4 2020e n.s. n.s. n.s.	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 -18,1 2021e 62 60 -8 68 0 0 4,7 2021e n.s. n.s. n.s.	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 72 70 -8 94 0 0 -11,6 2022e 70,6% 50,7% 55,1% 27,1%	12,5 0,0 12,5 0,0 0,0 0,0 0,0 12,5 2023e 82 79 -8 115 0 0 -24,1 2023e 85,9% 85,9% 85,9% 81,19% 30,8% 18,7%	0,0 26,7 0,0 0,0 0,0 0,0 26,7 2024e 91 89 -8 151 0 0 -50,7 2024e 43,6% 43,6% 50,3% 23,6%
Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios EBITDA margin EBITA margin Adjusted Net Profit/Sales ROCE	-3,2 -0,2 -3,4 5,1 16,9 0,0 18,5 2017 25 22 -8 34 0 0 -17,2 2017 n.s. n.s.	-7,0 -7,6 0,3 -7,3 0,1 11,9 0,0 0,0 4,7 2018 32 29 -9 45 0 0 -22,6 2018 n.s. n.s.	-12,4 0,3 -12,1 0,5 18,4 0,0 0,0 6,7 2019 42 40 -8 61 0 0 -26,7 2019 n.s. n.s.	-13,1 0,0 -13,1 0,0 20,0 0,0 0,0 6,9 2020e 52 50 -8 77 0 0 -13,4 2020e n.s. n.s.	-18,1 0,0 -18,1 0,0 0,0 0,0 0,0 0,0 -18,1 2021e 62 60 -8 68 0 0 4,7 2021e n.s. n.s.	16,3 0,0 16,3 0,0 0,0 0,0 0,0 16,3 2022e 72 70 -8 94 0 0 -11,6 2022e 70,6% 50,7% 55,1%	12,5 0,0 12,5 0,0 0,0 0,0 0,0 12,5 2023e 82 79 -8 115 0 0 -24,1 2023e 85,9% 81,1% 30,8%	0,0 26,7 0,0 0,0 0,0 0,0 26,7 2024e 91 89 -8 151 0 0 -50,7 2024e 43,6% 43,6% 37,0% 50,3%



SWOT ANALYSIS

STRENGTHS

- Epigenetic platform
- ☐ Numerous clinical development programs
- Solid cash position


WEAKNESS

- No partnership
- Numerous failures in lead indication (AD)
- ☐ Tight competition in oncology indications

OPPORTUNITIES THREATS

- Potential partnership agreement
- Expansion indications for clinical programs
- Clinical and regulatory risks
- Commercial risks
- Legal risks

SHARE PRICE CHANGE FOR 5 YEARS



DETECTION OF CONFLICTS OF INTEREST

	Corporate Finance	Treasury stocks holding	Prior communication to company	Analyst's personal interest	Liquidity contract	Listing Sponsor	Research Contract
Oryzon Genomics	Non	Non	Non	Non	Non	Non	Oui

DISCLAIMER

The present document does not constitute and is not part of any offer or solicitation for the purchase or sale of stocks and/or bonds issued by the issuers. While all the necessary precautions have been taken in order to assure that the facts mentioned in this present document are accurate and that the forecasts, opinions and scenarios contained in it are sincere and reasonable, Invest Securities has not verified the information contained in the present document and consequently neither Invest Securities nor any of its corporate officers, managers or employees may be held liable in any manner for its content. No guarantee is given regarding the accuracy, sincerity or completeness of the information contained in the present document. No persons accept any liability for any losses whatsoever resulting from the use of the present document or its contents or in any way linked to the present document. Research reports (including their preparation and distribution) are subject to the terms of Regulation (EU) no. 596/2014 of the European Parliament concerning market abuses. The present document is uniquely destined for (A) persons supplying third party portfolio management investment services and/or (B) qualified investors acting on their own behalf as defined in articles L.411-2, D.411-1 and D.411-4 of the Monetary and Financial Code. The present document has been supplied to you on a confidential basis and may not be reproduced or transmitted, in whole or part, to any other person or be published.

DIRECTION

BIOTECH

Marc-Antoine Guillen CEO

+33 1 44 88 77 80 maguillen@invest-securities.com

Jean-Emmanuel Vernay

Managing Director

+33 1 44 88 77 82 jevernay@invest-securities.com

Anne Bellavoine

Deputy Managing Director

+33 1 55 35 55 75 abellavoine@invest-securities.com

Pascal Hadjedj

Deputy Managing Director and Head of Primary Market Sales

+33 1 55 35 55 61 phadjedj@invest-securities.com

FINANCIAL ANALYSIS

Maxime Dubreil

Head of Equity Research

+33 1 44 88 77 98 mdubreil@invest-securities.com

Stéphane Afonso

Real Estate

+33 1 73 73 90 25 safonso@invest-securities.com

Christian Guyot

Consumer Goods

+33 1 80 97 22 01 cguyot@invest-securities.com

Thibault Morel

Technology

+33 1 44 88 77 97 tmorel@invest-securities.com

Johann Carrier

Stock-Picking

+33 1 44 88 77 88 jcarrier@invest-securities.com

Matthieu Lavillunière, CFA

Technology

+33 1 73 73 90 34 mlavilluniere@invest-securities.com

Jean-Louis Sempé

Automotive

+33 173 73 90 35 jlsempe@invest-securities.com

Bruno Duclos

Real Estate

+33173739025 bduclos@invest-securities.com

Ludovic Martin, CFA

Consumer Goods

+33 173 73 90 36 Imartin@invest-securities.com

Thibaut Voglimacci

Medtechs / Biotechs

+33 1 44 88 77 95 tvoglimacci@invest-securities.com

Benoît Faure-Jarrosson

Real Estate

+33 173 73 90 25 bfaure-jarrosson@invest-securities.com

Vladimir Minot

Real Estate

+33 173 73 90 25 vminot@invest-securities.com

TRADING FLOOR

François Habrias

Institutional Sales

+33 1 55 35 55 70 fhabrias@invest-securities.com

Kaspar Stuart

Institutional Sales

+33 1 55 35 55 65 kstuart@invest-securities.com

Dominique Humbert

Sales trading

+33 1 55 35 55 64 dhumbert@invest-securities.com

Renaud Vallette Viallard

Institutional Sales

+33 172 38 26 32 rvv@invest-securities.com

Bertrand Le Mollé-Montanguon

Institutional Sales

+33 1 55 35 55 74 blmm@invest-securities.com

Frédéric Vals

Institutional Sales

+33 1 55 35 55 71 fvals@invest-securities.com

Ralph Olmos

Institutional Sales

+33 1 55 35 55 72 rolmos@invest-securities.com

CORPORATE BROKING & ISSUER MARKETING

Thierry Roussilhe

Head of CB & Issuer Marketing

+33 1 55 35 55 66 troussilhe@invest-securities.com

Claude Bouyer

Senior Advisor

+33 1 44 88 88 02 cbouyer@invest-securities.com